NCT07519018Not yet recruiting
TIS for Drug Resistant TLE
Study on the Effect of Temporal Interference Stimulation in the Therapy of Drug Resistant Temporal Lobe Epilepsy
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
Temporal interference (TI) stimulation is a new neuromodulation method. Compared with traditional neuromodulation therapy, TI has deep targeting and focusing, and it has been confirmed to modulate sleep, cognition, and movement disorders. Recent study shown that TI stimulation targeting the hippocampus could significantly reduce epileptiform discharges, but its efficacy on seizures was still unclear. Therefore, the aim of this study is to observe the therapeutic effect of TI stimulation targeting the hippocampus in patients with refractory temporal lobe epilepsy (TLE) for 5 days, and to provide support for clinical trials of non-invasive treatment of refractory TLE.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 1 Apr 2026
- Start date
- 15 Apr 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Xijing Hospital
- Diseases
- Epilepsy
- NCT number
- NCT07519018
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 15 Apr 2026 to the primary completion date, 30 Apr 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with contraindications to TI stimulation, fMRI examination or EEG examination, metal implants (pacemakers, metal dentures, metal IUD rings, etc.), or claustrophobia;
Other illness
- The anti-seizure medication therapy was adjusted during the treatment and follow-up period;
- Patient with other systemic diseases leading to nervous system involvement and seizures;
- Patients with severe infection, cerebrovascular disease, malignant tumor and other diseases, accompanied by severe dysfunction of heart, liver, kidney and other organs, or accompanied by severe mental or cognitive impairment, or intractable hyperglycemia, or long-term use of corticosteroids;
Other
- Patient in status epilepticus;
- Patient with pregnant or lactating;
- Participating in other clinical trials;
- Patients or their family members withdrew informed consent.
Who the study is looking for
- 18 to 65 years old;
- According to the 2010 International League Against Epilepsy (ILAE) diagnostic criteria for drug-resistant epilepsy;
- Temporal lobe epilepsy assessed by semiology, video electroencephalogram, and imaging;
- The duration of epilepsy was ≥2 years, and the average seizure frequency was ≥2 times per month in the 3 months before enrollment;
- Taking two or more antiepileptic drugs and continuing the same drug regimen for the duration of the trial;
- Could cooperate with the completion of treatment and related examinations;
- Patients and their family members fully understood and voluntarily signed the informed consent.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.